HAMILTON, Bermuda, Aug. 23, 2017 (GLOBE NEWSWIRE) -- Incysus, Ltd, a biopharmaceutical company focused on delivering an innovative γδ T cell immunotherapy for the treatment of cancers, announced that its collaborator and scientific co-founder, Lawrence Lamb, MN, PhD, will be presenting at the Immuno-Oncology Summit in Boston on Wednesday, August 30th, 2017 (http://immuno-oncologysummit.com/T-Cell/).
“With the advancement of many new immuno-oncology technologies, we are excited to have Dr. Lamb speak about our innovative approach and latest progress developing a novel therapy that uniquely allows the combination of high-dose chemotherapy with an immunotherapy for the treatment of cancer,” said William Ho, Chief Executive Officer of Incysus.
Dr. Lamb will be presenting at 8:15am (EDT) in the Adoptive T Cell Therapy session. His presentation titled, “The End Game: Adjuvant γδ T Cell-Based Strategies for Consolidation and Eradication of Residual Cancer” will discuss how expanded and activated γδ T cells can significantly extend relapse-free survival (RFS) in human and animal studies of hematopoietic and solid cancers. Using glioblastoma multiforme (GBM) as a model, Dr. Lamb will show that simultaneous chemotherapy-induced upregulation of NKG2DL expression and infusion of chemotherapy-resistant gene-modified γδ T cells can result in significant RFS in a patient-derived xenograft model. Dr. Lamb will discuss translation and early trials of these strategies in leukemia and GBM.
About Lawrence Lamb, MN, PhD
Dr. Lamb is a Clinical Laboratory Immunologist and Professor of Medicine at the University of Alabama at Birmingham (UAB) specializing in transplantation immunology. He also holds appointments in Pathology and Pediatrics and is board-certified by the Oncology Nursing Certification Corporation for Advanced Practice in Oncology Nursing (AOCNS). Dr. Lamb directs the UAB Cell Therapy Laboratory in the Section of Bone Marrow Transplant and Cellular Therapy. Dr. Lamb was the first to describe homeostatic reconstitution of γδ T cells in patients who receive γδ T cell-depleted bone marrow grafts as well as an association between γδ T cell recovery and disease-free survival in allogeneic bone marrow transplants. He currently directs research programs for evaluation and translation of γδ T cell-based therapies for GBM and leukemia. Dr. Lamb's research has been funded by the NINDS, NCI, Elsa Pardee Foundation, Leukemia and Lymphoma Society, the Brendan Franco Foundation, and the Southeastern Brain Tumor Foundation. He also held the National Brain Tumor Society's Samuel Gerson Leadership Chair for Glioblastoma Research from 2008-2010. Dr. Lamb serves on several national and international committees related to cell and gene therapy.
About Incysus, Ltd.
Incysus is a Bermuda incorporated company focused on delivering a novel off-the-shelf cell therapy for the treatment of cancer. By using genetically modified γδ T cells, our technology addresses the challenges that immunotherapies face targeting cold, low mutation, cancers. The Company's immuno-oncology programs include activated and gene modified adoptive cellular therapies that protect cells from chemotherapy and allow novel combinations to disrupt the tumor microenvironment and more selectively target cancer cells.